Prof Constantine Tam
Clinical (Professor)
Department of Medicine
930 Scholarly works
7 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Journal article
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
DOI: 10.1182/bloodadvances.20210056212022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2019
Research grants (ARC, NHMRC, MRFF)
The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
2017
Research Grant
Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
RECENT SCHOLARLY WORKS
2026
Journal article
First-line treatment for CLL in the era of targeted therapy
DOI: 10.1038/s41408-025-01434-22026
Journal article
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
DOI: 10.1182/bloodadvances.20260201232026
Journal article
Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.
DOI: 10.1182/bloodadvances.20260201972026
Journal article
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.
DOI: 10.1182/bloodadvances.20260216182026
Journal article
Risk-Guided Disease Management to Prevent Heart Failure in Adult Cancer Survivors of Previous Cardiotoxic Cancer Treatments (REDEEM) Trial
DOI: 10.1016/j.hlc.2026.07.0082026
Journal article
Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment
DOI: 10.1016/j.bneo.2026.1002602026
Journal article
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
DOI: 10.1111/imj.705032026
Journal article
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study
DOI: 10.1111/bjh.70620